BioNTech won’t proceed with further development of its BNT111 cancer vaccine candidate in a specific late-stage refractory ...

Analysts expect BioNTech to report an earnings per share (EPS) of $0.75. Investors in BioNTech are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive ...

MAINZ, Germany, October 28, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company’s Innovation Series R&D Day at 09:00 a.m. Eastern ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued large cap stocks to buy right now. On October 24, Pfizer Singapore and ...

Biontech Se Sponsored Adr (($BNTX)) announced an update on their ongoing clinical study. BioNTech SE is currently sponsoring a Phase II clinical ...

BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep ...

BioNTech is bolstering its artificial intelligence and machine learning capabilities through the £362 million acquisition of InstaDeep, a startup whose technology has already supported the company’s ...

Moderna is taking Pfizer and Germany's BioNTech to court, claiming the rival drugmakers copied its technology in developing their COVID-19 vaccine. In documents filed in U.S. District Court in ...